Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)
China · Delayed Price · Currency is CNY 58.56
+0.23 (0.39%)
Apr 29, 2026, 3:00 PM CST
SHA:688621 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,189 | 1,222 | 1,077 | 930.98 | 676.39 | 492.86 |
Other Revenue | - | - | 1.61 | 1.14 | 0.21 | 0.79 |
| 1,189 | 1,222 | 1,078 | 932.12 | 676.61 | 493.65 | |
Revenue Growth (YoY) | 12.44% | 13.33% | 15.70% | 37.76% | 37.06% | 42.12% |
Cost of Revenue | 537.3 | 560.8 | 537.33 | 403.77 | 301.15 | 229.97 |
Gross Profit | 651.2 | 661.45 | 541.14 | 528.35 | 375.46 | 263.68 |
Selling, General & Admin | 212.38 | 193.64 | 150.44 | 153.24 | 110.81 | 85.63 |
Research & Development | 159.32 | 161.56 | 171.94 | 123.68 | 89.69 | 47.58 |
Other Operating Expenses | -9.94 | -17.52 | 0.76 | 0.2 | 0.16 | 0.04 |
Operating Expenses | 361.76 | 337.67 | 364.82 | 334.89 | 219.32 | 143.72 |
Operating Income | 289.44 | 323.78 | 176.32 | 193.46 | 156.14 | 119.97 |
Interest Expense | - | - | -16.11 | -12.18 | -9.7 | -3.56 |
Interest & Investment Income | 4.81 | 4.97 | 5.67 | 8.53 | 8.78 | 2.52 |
Other Non Operating Income (Expenses) | -58.49 | -80.92 | -2.66 | -2.47 | -0.96 | -0.72 |
EBT Excluding Unusual Items | 235.76 | 247.82 | 163.22 | 187.35 | 154.25 | 118.21 |
Gain (Loss) on Sale of Investments | - | - | -1.82 | - | - | - |
Gain (Loss) on Sale of Assets | 0.65 | 0.65 | -0.31 | -0.71 | -0.25 | -0.51 |
Asset Writedown | -34.48 | -39.72 | - | - | - | - |
Other Unusual Items | - | - | 14.9 | 6.76 | 15.14 | 4.4 |
Pretax Income | 201.92 | 208.75 | 175.99 | 193.4 | 169.14 | 122.1 |
Income Tax Expense | 0.33 | -1.76 | 6.97 | 10.5 | 10.43 | 13.31 |
Earnings From Continuing Operations | 201.6 | 210.51 | 169.01 | 182.9 | 158.7 | 108.79 |
Minority Interest in Earnings | -6.68 | -6.65 | 8.4 | 1.86 | -2.23 | -3.13 |
Net Income | 194.92 | 203.87 | 177.41 | 184.76 | 156.47 | 105.66 |
Net Income to Common | 194.92 | 203.87 | 177.41 | 184.76 | 156.47 | 105.66 |
Net Income Growth | 45.21% | 14.91% | -3.98% | 18.08% | 48.09% | 45.81% |
Shares Outstanding (Basic) | 111 | 110 | 112 | 112 | 112 | 98 |
Shares Outstanding (Diluted) | 111 | 110 | 112 | 112 | 112 | 98 |
Shares Change (YoY) | -1.11% | -2.38% | 0.28% | 0.19% | 14.09% | 16.84% |
EPS (Basic) | 1.76 | 1.86 | 1.58 | 1.65 | 1.40 | 1.08 |
EPS (Diluted) | 1.76 | 1.86 | 1.58 | 1.65 | 1.40 | 1.08 |
EPS Growth | 46.83% | 17.72% | -4.24% | 17.86% | 29.80% | 24.80% |
Free Cash Flow | -33.67 | 50.78 | 1.54 | 19.9 | 0.09 | 3.29 |
Free Cash Flow Per Share | -0.30 | 0.46 | 0.01 | 0.18 | 0.00 | 0.03 |
Dividend Per Share | - | - | 0.163 | 0.165 | 0.429 | 0.189 |
Dividend Growth | - | - | -1.21% | -61.50% | 126.41% | - |
Gross Margin | 54.79% | 54.12% | 50.18% | 56.68% | 55.49% | 53.41% |
Operating Margin | 24.35% | 26.49% | 16.35% | 20.76% | 23.08% | 24.30% |
Profit Margin | 16.40% | 16.68% | 16.45% | 19.82% | 23.13% | 21.40% |
Free Cash Flow Margin | -2.83% | 4.15% | 0.14% | 2.14% | 0.01% | 0.67% |
EBITDA | 319.62 | 353.33 | 201.69 | 215.47 | 173.19 | 131.47 |
EBITDA Margin | 26.89% | 28.91% | 18.70% | 23.12% | 25.60% | 26.63% |
D&A For EBITDA | 30.17 | 29.55 | 25.38 | 22.01 | 17.05 | 11.5 |
EBIT | 289.44 | 323.78 | 176.32 | 193.46 | 156.14 | 119.97 |
EBIT Margin | 24.35% | 26.49% | 16.35% | 20.76% | 23.08% | 24.30% |
Effective Tax Rate | 0.16% | - | 3.96% | 5.43% | 6.17% | 10.90% |
Revenue as Reported | - | - | 1,078 | 932.12 | 676.61 | 493.65 |
Advertising Expenses | - | - | 0.58 | 1.69 | 1.17 | 1.13 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.